Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review

被引：0
作者：
Nasrin Abulhasanbeigi Gallehzan
Majid Khosravi
Khosro Jamebozorgi
Nazanin Mir
Habib Jalilian
Samira Soleimanpour
Saeed Hoseini
Aziz Rezapour
Abbas Eshraghi
机构：
[1] Health Management Research Institute,Health Management and Economics Research Center
[2] Iran University of Medical Sciences,Faculty of Medicine
[3] Zabol University of Medical Sciences,Department of Health Services Management, School of Health
[4] Ahvaz Jundishapur University of Medical Sciences,Department of Medical Library and Information Science, School of Health Management and Information Sciences
[5] Iran University of Medical Sciences,Health Management and Economics Research Center, School of Health Management and Information Sciences
[6] Iran University of Medical Sciences,Student Research Committee
[7] Tabriz University of Medical Sciences,undefined
来源：
Health Economics Review | / 14卷
关键词：
Disease-modifying drugs; Relapsing–remitting multiple sclerosis; Cost-utility analysis; Cost-effectiveness analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 320 条
[1]  
Sperandeo K(2011)Managed approaches to multiple sclerosis in special populations J Managed Care Pharm. 17 1-215
[2]  
Nogrady L(2003)Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: Evaluating disease modifying treatments in multiple sclerosis BMJ 326 522-20
[3]  
Moreo K(2013)Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis Am J Manag Care 19 S15-1821
[4]  
Prostko CR(2020)Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS Mult Scler J 26 1816-133
[5]  
Chilcott J(2020)Incidence and prevalence of multiple sclerosis in Persian gulf area: a systematic review and meta-analysis Multiple Scleros Related Disord 40 101959-911
[6]  
Miller DH(2018)Depression in multiple sclerosis: epidemiology, aetiology, diagnosis and treatment CNS Drugs 32 117-286
[7]  
McCabe C(1996)Defining the clinical course of multiple sclerosis: results of an international survey Neurology 46 907-57
[8]  
Tappenden P(2014)Defining the clinical course of multiple sclerosis: the 2013 revisions Neurology 83 278-1619
[9]  
O'Hagan A(2015)Identifying and addressing unmet therapeutic needs in MS J Clin Psych. 76 0-1636
[10]  
Cooper NJ(2017)Cost-utility of first-line disease-modifying treatments for relapsing–remitting multiple sclerosis Clin Therapeut. 39 537-870
12345678910